<SEC-DOCUMENT>0001437749-13-002682.txt : 20130312
<SEC-HEADER>0001437749-13-002682.hdr.sgml : 20130312
<ACCEPTANCE-DATETIME>20130312144049
ACCESSION NUMBER:		0001437749-13-002682
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130311
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130312
DATE AS OF CHANGE:		20130312

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GeoVax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		13683644

	BUSINESS ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080
		BUSINESS PHONE:		678-384-7220

	MAIL ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Geovax Labs, Inc.
		DATE OF NAME CHANGE:	20061002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>govx20130311_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD><TITLE>govx20130311_8k.htm</TITLE>
<!-- Created by RDG HTML Converter -->
</HEAD>
<BODY style="FONT-FAMILY: Times New Roman; MARGIN-LEFT: 10px; FONT-SIZE: 10pt; MARGIN-RIGHT: 10px">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA87>
<HR style="WIDTH: 100%; HEIGHT: 4px; COLOR: #000000">

<HR style="POSITION: relative; WIDTH: 100%; HEIGHT: 1px; COLOR: #000000; TOP: -12px">
<FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA115></P></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA82><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 18pt"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA83><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>WASHINGTON, D.C. 20549 </B></FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA114></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA113></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA112></P>
<HR style="TEXT-ALIGN: center; WIDTH: 21%; COLOR: #000000">
</FONT>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA85></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA9><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 18pt"><B>FORM 8-K </B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA10><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA11><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>CURRENT REPORT </B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA12><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Pursuant to Section 13 or 15(d) of the </B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA13><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Securities Exchange Act of 1934 </B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA14><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA15><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Date of report (Date of earliest event reported): March 11, 2013</B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA16><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA17><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">
<HR style="TEXT-ALIGN: center; WIDTH: 21%; COLOR: #000000">
</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA84></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA19><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 18pt"><B>GEOVAX LABS, INC.</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA20><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>(Exact name of registrant as specified in Charter) </B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA21><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>&nbsp;</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA22><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA23><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<TABLE style="WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=TBL35  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 31.3%; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA24><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Delaware</B></FONT></P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: bottom">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA25><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 31.3%; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA26><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>000-52091</B></FONT></P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: bottom">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA27><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 31.3%; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA28><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>87-0455038</B></FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 31.3%; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA29><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>(State or other jurisdiction of</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA30><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>incorporation or organization)</B></FONT></P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: bottom">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA31><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 31.3%; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA32><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>(Commission File No.)</B></FONT></P></TD>
<TD style="WIDTH: 3%; VERTICAL-ALIGN: bottom">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA33><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 31.3%; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA34><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>(IRS Employee Identification No.)</B></FONT></P></TD></TR></TABLE>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA36><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA37><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>1900 Lake Park Drive</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA38><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Suite 380</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA39><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Smyrna, Georgia 30080</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA40><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>(Address of Principal Executive Offices) </B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA41><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA42><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>(678) 384-7220</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA43><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>(Issuer Telephone number) </B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA44><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA46><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2 below).</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA47><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA48><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA49><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA50><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR240.14a-12)</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA51><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA52><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA53><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA54><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">[ ] Pre-commencement communications pursuant to Rule 13e-4&#169; under the Exchange Act (17 CFR 240.13(e)-4(c))</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt">&nbsp;<FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT></P>
<DIV style="DISPLAY: block"  height:8px;>
<HR style="WIDTH: 100%; HEIGHT: 1px; COLOR: #000000">

<HR style="POSITION: relative; WIDTH: 100%; HEIGHT: 4px; COLOR: #000000; TOP: -12px">
</DIV>
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA88.1>&nbsp;</P>
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px">&nbsp;</P>
<P style="TEXT-ALIGN: center; MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px">###</P>
<P style="TEXT-ALIGN: center; MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"></P>
<P style="TEXT-ALIGN: center; MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px">&nbsp;</P>
<DIV style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" id=PGBK88 >
<DIV style="TEXT-ALIGN: center; WIDTH: 100%" id=PGFTR88 >&nbsp;</DIV>
<DIV style="TEXT-ALIGN: center; WIDTH: 100%; DISPLAY: inline; FONT-SIZE: 10pt" id=PGNUM88 >&nbsp;</DIV>
<HR style="PAGE-BREAK-AFTER: always; WIDTH: 100%; HEIGHT: 2px; COLOR: #000000" noShade>

<DIV style="TEXT-ALIGN: center; WIDTH: 100%" id=PGHDR88 >&nbsp;</DIV></DIV>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA81><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT>&nbsp;</P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; MARGIN: 0pt" id=PARA89><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#147;registrant&#148;) from time to time with the Securities and Exchange Commission (collectively the &#147;Filings&#148;) contain forward looking statements and information that are based upon beliefs of, and information currently available to, the registrant's management as well as estimates and assumptions made by the registrant's management. When used in the Filings the words &#147;anticipate&#148;, &#147;believe&#148;, &#147;estimate&#148;, &#147;expect&#148;, &#147;future&#148;, &#147;intend&#148;, &#147;plan&#148; or the negative if these terms and similar expressions as they relate to the registrant or the registrant's management identify forward looking statements. Such statements reflect the current view of the registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the registrant's industry, operations and results of operations and any businesses that may be acquired by the registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA90><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA91><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Item 2.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;Results of Operations and Financial Condition</B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA92><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 72pt; MARGIN: 0pt" id=PARA93><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">On March 11, 2013 we issued a press release reporting our results of operations for the year ended December 31, 2012. A copy of the press release is attached to this Current Report.</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA94><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA95><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;Financial Statements and Exhibits</B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA96><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 72pt; MARGIN: 0pt" id=PARA97><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Exhibit 99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Press Release</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -63pt; MARGIN: 0pt 0pt 0pt 63pt" id=PARA98><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA99><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>SIGNATURES</B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA100><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 72pt; MARGIN: 0pt" id=PARA101><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA102><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA103><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Dated: March 12, 2013</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA104><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 216pt; MARGIN: 0pt 0pt 0pt 117pt" id=PARA105><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">GEOVAX LABS, INC.</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt 0pt 0pt 117pt" id=PARA106><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt 0pt 0pt 117pt" id=PARA107><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt 0pt 0pt 117pt" id=PARA108><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 216pt; MARGIN: 0pt 0pt 0pt 117pt" id=PARA109><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">By:<U>&nbsp;&nbsp;&nbsp;/s/ Mark W. Reynolds&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 216pt; MARGIN: 0pt 0pt 0pt 117pt" id=PARA110><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mark W. Reynolds </FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 216pt; MARGIN: 0pt 0pt 0pt 117pt" id=PARA111><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer</FONT></P>
<P style="LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt">&nbsp;</P></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>govx20130311_8kex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML><HEAD><TITLE>govx20130311_8kex99-1.htm</TITLE>
<!-- Created by RDG HTML Converter -->
</HEAD>
<BODY style="FONT-FAMILY: Times New Roman; MARGIN-LEFT: 10px; FONT-SIZE: 10pt; MARGIN-RIGHT: 10px">
<P style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA1><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>&nbsp;Exhibit 99.1</B></FONT></P>
<P style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; MARGIN: 0pt"><STRONG></STRONG>&nbsp;</P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt"><STRONG></STRONG><IMG src="image1.jpg">&nbsp;</P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt"><STRONG></STRONG>&nbsp;<STRONG></STRONG>&nbsp;&nbsp;</P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt"><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B></B><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 12pt"><B>GeoVax Labs Reports 2012 Financial Results and Progress</B></FONT></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA4><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>&nbsp;</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA5><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>Two Ongoing Clinical Trials for Preventive and Therapeutic HIV/AIDS Vaccine</I></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA6><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>&nbsp;</I></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA7><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>Additional Therapeutic Trial to Start in Mid-2013</I></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA8><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>&nbsp;</B></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA9><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>&nbsp;</B></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA10><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>ATLANTA, GA, March 11, 2013 &#150;</B> GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biotechnology company developing innovative, patented HIV/AIDS vaccines, today announced its financial results for the year ended December 31, 2012 and provided a business update.</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA11><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA12><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&#147;GeoVax continues its successful, steady progress with the clinical development of HIV/AIDS vaccines for both preventive and therapeutic applications,&#148; said David Dodd, GeoVax&#146;s Chairman of the Board. &#147;With generous support from the National Institutes of Health (NIH) in the form of both research grants and clinical trial support, our preventive HIV/AIDS vaccine has advanced to a leadership position, and is currently the only vaccine candidate being considered for efficacy trials for the clade B subtype of the HIV virus prevalent in the Americas, Europe, Australia and Japan.&#148;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA13><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA14><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The following table reflects the current development status of GeoVax&#146;s HIV/AIDS vaccine candidates:</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT></P>
<TABLE style="WIDTH: 96.5%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 3.5%" id=DTAB32  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="TEXT-ALIGN: left; WIDTH: 14%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA18><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B></B></FONT>&nbsp;</P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt"><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Vaccine</B></FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt"><U><B>Candidate</B></U></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 16%"></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 28%" colSpan=2>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA25><U><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B></B></FONT></U>&nbsp;</P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt"><U><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B></B></FONT></U>&nbsp;</P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt"><U><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Indication</B></FONT></U><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 20%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA27><U><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B></B></FONT></U>&nbsp;</P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt"><U><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B></B></FONT></U>&nbsp;</P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt"><U><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Stage of Development</B></FONT></U><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 11%"></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 11%"><STRONG>&nbsp;</STRONG>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA21><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><STRONG>Clinical</STRONG></FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA29><U><B>Trial Sponsor</B></U></P></TD></TR></TABLE>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA30><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><U>Clade B Vaccines (Americas, Western Europe)</U></FONT><BR>
<TABLE style="WIDTH: 96.5%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 3.5%" id=DTAB32  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="TEXT-ALIGN: left; WIDTH: 1%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA33><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 13%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA34><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">DNA/MVA</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 16%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA35><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 28%" colSpan=2>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA36><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Prevention </FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 20%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA38><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Clinical &#150; Phase 2a completed</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 11%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA39><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 11%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA40><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">NIH/HVTN</FONT></P></TD></TR></TABLE>
<TABLE style="WIDTH: 96.5%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 3.5%" id=DTAB42  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="TEXT-ALIGN: left; WIDTH: 1%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA43><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 13%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA44><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">DNA-G/MVA</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 16%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA45><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 28%" colSpan=2>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA46><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Prevention (2nd-generation)</FONT>&nbsp;<FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 20%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA48><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Clinical &#150; Phase 1</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 11%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA49><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 11%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA50><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">NIH/HVTN</FONT></P></TD></TR>
<TR>
<TD style="TEXT-ALIGN: left; WIDTH: 1%"></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 13%"></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 16%"></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 28%" colSpan=2></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 20%">Planning &#150; Phase 2 efficacy&nbsp;</TD>
<TD style="TEXT-ALIGN: left; WIDTH: 11%"></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 11%">NIH/HVTN</TD></TR>
<TR>
<TD style="TEXT-ALIGN: left; WIDTH: 1%"></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 13%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA55><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">DNA/MVA</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 16%"></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 28%" colSpan=2>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA57><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Therapeutic (treatment interruption)</FONT>&nbsp;<FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 20%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA59><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Clinical &#150; Phase 1/2</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 11%"></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 11%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA61><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">GeoVax</FONT></P></TD></TR>
<TR>
<TD style="TEXT-ALIGN: left; WIDTH: 1%"></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 13%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA65><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">DNA-G/MVA</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 16%"></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 28%" colSpan=2>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA67><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Therapeutic (drug combo)</FONT>&nbsp;<FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 20%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA69><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Planning &#150; Phase 1</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 11%"></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 11%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA71><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">NIH/IMPAACT</FONT></P></TD></TR></TABLE></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA73><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><U></U></FONT>&nbsp;</P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt"><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><U>Clade C Vaccines (South Africa, India)</U></FONT></P>
<TABLE style="WIDTH: 96.5%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 3.5%" id=DTAB75  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="TEXT-ALIGN: left; WIDTH: 1%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA76><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 13%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA77><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">DNA-G/MVA</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 16%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA78><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 28%" colSpan=2>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA79><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Prevention</FONT>&nbsp;<FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 20%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA81><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Research/Preclinical</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 11%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA82><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 11%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA83><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">n/a</FONT></P></TD></TR></TABLE>
<TABLE style="WIDTH: 96.5%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 3.5%" id=DTAB85  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="TEXT-ALIGN: left; WIDTH: 1%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA86><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 13%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA87><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">DNA-G/MVA</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 16%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA88><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 28%" colSpan=2>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA89><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Therapeutic</FONT>&nbsp;<FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 20%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA91><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Research/Preclinical</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 11%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA92><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P></TD>
<TD style="TEXT-ALIGN: left; WIDTH: 11%">
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA93><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">n/a</FONT></P></TD></TR></TABLE>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA94><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA95><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Clinical Development Highlights:</B></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA96><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>&nbsp;</B></FONT></P>
<TABLE style="WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=MTAB98  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA99><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&#9679;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I></I></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA100><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>Preventive Vaccine &#150; Phase 2a Trial</I>. The Phase 2a trial (HVTN 205) of GeoVax&#146;s preventive HIV/AIDS vaccine has been completed. Results of this trial were presented in September 2012 by the HIV Vaccine Trials Network (HVTN) at the AIDS Vaccine 2012 Conference in Boston. HVTN 205 confirmed the Phase 1 results, with the GeoVax vaccine demonstrating an excellent safety profile and reproducible T cell and antibody immune responses. The Company expects formal publication of the full study results by the end of 2013.</FONT></P></TD></TR></TABLE>
<TABLE style="WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=MTAB102  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA103><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&#9679;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I></I></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA104><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>Preventive Vaccine (2nd-generation) &#150; Phase 1 Trial</I>. Patient enrollment was completed in December for the Phase 1 trial testing the safety of GeoVax&#146;s second-generation vaccine (GM-CSF adjuvanted). Preclinical testing of this vaccine yielded superb results, with a 90 percent reduction in infection (per exposure) which translated to 70 percent of vaccinated animals being protected against 12 repeated, highly virulent, rectal challenges with a simian homolog of HIV. GeoVax expects the Phase 1 trial to be completed in the second half of 2013.</FONT></P></TD></TR></TABLE>
<TABLE style="WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=MTAB106  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA107><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&#9679;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I></I></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA108><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>Preventive Vaccine (2nd-generation) &#150; Phase 2 Efficacy Trial Planning</I>. Pending successful outcome of Phase 1 testing of the second-generation vaccine, GeoVax expects to advance this version of its preventive vaccine into Phase 2 efficacy testing in high-risk individuals, expected to begin in 2014. The Company is currently in discussions with the HVTN regarding protocol development and anticipates knowing more about the trial design and the government funding consortium in late 2013.</FONT></P></TD></TR></TABLE>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" id=PARA450></P>
<P style="TEXT-ALIGN: center"><B>MORE</B></P>
<DIV style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" id=PGBK222 >
<DIV style="TEXT-ALIGN: center; WIDTH: 100%" id=PGFTR222 >&nbsp;</DIV>
<DIV style="TEXT-ALIGN: center; WIDTH: 100%; DISPLAY: inline; FONT-SIZE: 10pt" id=PGNUM222 >&nbsp;</DIV>
<HR style="PAGE-BREAK-AFTER: always; WIDTH: 100%; HEIGHT: 2px; COLOR: #000000" noShade>

<DIV style="TEXT-ALIGN: left; WIDTH: 100%" id=PGHDR222 >&nbsp;</DIV></DIV>
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA222.2>&nbsp;</P>
<TABLE style="WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=MTAB110  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA111><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&#9679;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I></I></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA112><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>Therapeutic Vaccine &#150; Treatment Interruption Study</I>. The Company&#146;s ongoing Phase 1/2 &#147;treatment interruption&#148; clinical trial, investigating the use of its vaccine for treatment of individuals already infected with HIV, completed enrollment at the end of 2012. This pilot trial is designed to assess whether the vaccine is safe and immunogenic (i.e. induces immune responses) in individuals who have controlled their infections using oral drug medication. Following vaccination, the trial includes a short period of drug-interruption to evaluate the ability of the vaccine to control the infection in the absence of continuing drug therapy. GeoVax expects to see data readouts from this study during 2013, which might indicate the potential use of its vaccines to treat HIV infection, either as a standalone therapy or in conjunction with an oral drug regimen.</FONT></P></TD></TR></TABLE>
<TABLE style="WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=MTAB114  border=0 cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA115><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&#9679;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I></I></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-RIGHT: 0pt" id=PARA116><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>Therapeutic Vaccine &#150; Drug Combination. </I>Physician acceptance of a therapeutic HIV vaccine is increasingly being discussed as a combination therapy for HIV-positive individuals. By maintaining the standard oral drug medication and adding a vaccine, the medical community would be delivering the best possible care. In this regard, GeoVax is collaborating with the NIH and planning is underway for a second therapeutic clinical trial to begin in mid-2013. This Phase 1 trial will investigate the use of GeoVax&#146;s vaccine in combination with standard-of-care drug therapy in HIV-positive young adults. The Company expects this trial to be conducted by the International Maternal Pediatric Adolescent AIDS Clinical Trial Group (IMPAACT), a program supported by the NIH. Because of the mechanisms by which current oral drugs work, if the virus is in latent phase (non-replicating), the drugs are not effective, thus it is impossible to totally eradicate the virus. There is hope for a combination approach using the patient&#146;s own immune system stimulated by the vaccine, together with oral drugs to eradicate the virus&#151;thereby potentially offering a cure.</FONT></P></TD></TR></TABLE>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA117><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA118><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Robert T. McNally, Ph.D., GeoVax&#146;s President and CEO, commented, &#147;Our relationship with the National Institute of Allergy and Infectious Diseases (NIAID) of the NIH continues to be strong, and we look forward to their continued support of our vaccine development programs. Most recently, the NIH awarded us a grant of $1.9 million to begin the extension of our vaccine technology to the clade C subtype of the HIV virus prevalent in South Africa and India.&#148;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA119><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA120><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Dr. McNally continued, &#147;Looking ahead into 2013 and beyond, we are excited about the milestones we expect to achieve, including completion of the Phase 1 trial of our second-generation preventive vaccine, completion of the pilot Phase 1/2 trial of our therapeutic vaccine (treatment interruption trial), and initiation of a new, NIH-supported, Phase 1 trial of our therapeutic vaccine in combination with standard-of-care drug therapy. Each of these trials takes us further down the path toward the goal of an effective solution to the HIV/AIDS pandemic. We are very proud of the outstanding progress that our team continues to achieve in this critical development area for people worldwide.&#148;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA121><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA122><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Full Year 2012 Financial Results</B></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA123><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA124><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">GeoVax reported a net loss for the year ended December 31, 2012 of $2.1 million, or $0.12 per share, based on 18.3 million weighted average shares outstanding. For the year ended December 31, 2011, the Company reported a loss of $2.3 million, or $0.15 per share, based on 15.7 million weighted average shares outstanding.</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA125><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA126><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">The Company reported revenues of $2.7 million for 2012, related to grants from the NIH. This compares to $4.9 million of grant revenue reported in 2011. As of December 31, 2012, there is approximately $3.0 million in unused grant funds available for use through August 31, 2013 (the end of the grant project periods).</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA127><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA128><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Research and development (R&amp;D) expenses were $3.0 million in 2012, compared with $4.3 million in 2011. R&amp;D expenses include $1.8 million and $3.0 million for 2012 and 2011, respectively, in direct costs funded by NIH grants; and also include vaccine manufacturing costs and costs related to the Phase 1/2 clinical trial of the Company&#146;s therapeutic vaccine, being sponsored by GeoVax. Costs associated with the conduct of a Phase 2a clinical trial of GeoVax&#146;s preventative vaccine (completed during 2012) and a Phase 1 clinical trial of GeoVax&#146;s second-generation vaccine (both trials conducted by the HVTN) are being funded directly by the NIH and are therefore not reflected in GeoVax&#146;s financial statements.</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA129><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt"><B>MORE</B></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt">&nbsp;</P>
<DIV style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" id=PGBK223 >
<DIV style="TEXT-ALIGN: center; WIDTH: 100%" id=PGFTR223 >&nbsp;</DIV>
<DIV style="TEXT-ALIGN: center; WIDTH: 100%; DISPLAY: inline; FONT-SIZE: 10pt" id=PGNUM223 >&nbsp;</DIV>
<HR style="PAGE-BREAK-AFTER: always; WIDTH: 100%; HEIGHT: 2px; COLOR: #000000" noShade>

<DIV style="TEXT-ALIGN: left; WIDTH: 100%" id=PGHDR223 >&nbsp;</DIV></DIV>
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA223.2>&nbsp;</P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA130><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">General and administrative (G&amp;A) expenses were $1.8 million and $3.0 million in 2012 and 2011, respectively. G&amp;A expenses were lower during 2012 primarily due to lower legal costs, patent costs and stock-based compensation expense related to investment advisory fees and investor warrant extensions.</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA131><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA132><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">GeoVax reported cash balances of $1.0 million at December 31, 2012, as compared to $1.2 million at December 31, 2011. Summarized financial information is attached. Further information concerning the Company&#146;s financial position and results of operations are included in its Annual Report on Form 10-K, expected to be filed with the Securities and Exchange Commission before March 31, 2013.</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA133><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>&nbsp;</I></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff; MARGIN: 0pt" id=PARA134><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>About GeoVax</B></FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" ploc="BEFORE"><BR></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff; MARGIN: 0pt" id=PARA135><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV. GeoVax's vaccines are unique in expressing virus like particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as, the vaccines' safety. Successful results from a Phase 1 study supported a Phase 2a trial that was completed in the 3rd quarter of 2012. GeoVax's second-generation preventive vaccine is currently in phase 1 testing and is planned to progress to phase 2 efficacy testing, given safety and immunogenicity are as expected. Overall, the GeoVax vaccine, in various doses and combinations, has been tested in close to 500 humans. GeoVax is also enrolling patients in a Phase 1 therapeutic trial for individuals already infected with HIV. For more information, please visit&nbsp;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><U>www.geovax.com</U></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">.</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff; MARGIN: 0pt" id=PARA136><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff; MARGIN: 0pt" id=PARA137><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>About HIV/AIDS</B></FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" ploc="BEFORE"><BR></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff; MARGIN: 0pt" id=PARA138><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">HIV infection, which can lead to AIDS, is a pandemic that can affect anyone, regardless of race, gender, age, or sexual orientation. 33 million people are currently infected globally; it is estimated that there will be 2.5 million new infections this year. Since the beginning of the epidemic, more than a million people in the U.S. have contracted the virus. Every 9 1/2 minutes, someone in the U.S. is infected with HIV. Globally, HIV is the top killer among women of reproductive age. HIV is a worldwide disease with different subtypes (or clades) of the virus predominating in different regions of the world. Clade B is the predominant subtype in North America. Globally, most infections involve subtypes AG, B and C. GeoVax vaccines are currently designed to function against clade B.</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff; MARGIN: 0pt" id=PARA139><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">For more Information, please visit&nbsp;</FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><U>www.geovax.com</U></FONT><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">.</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff; MARGIN: 0pt" id=PARA140><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>&nbsp;</B></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff; MARGIN: 0pt" id=PARA141><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B><I>Forward-Looking Statements</I></B></FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" ploc="BEFORE"><BR></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff; MARGIN: 0pt" id=PARA142><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.</I></FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff; MARGIN: 0pt" id=PARA143><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA144><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>CONTACT</B></FONT></P>
<P style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt" ploc="AFTER"><BR></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA145><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Dian Griesel, Inc.</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA146><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Tom Caden</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA147><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Investor Relations</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA148><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Susan Forman or Laura Radocaj</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA149><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Public Relations</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA150><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">212-825-3210</FONT></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA151><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"></FONT>&nbsp;</P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt"><B>MORE</B></P>
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA224.1>&nbsp;</P>
<DIV style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" id=PGBK224 >
<DIV style="TEXT-ALIGN: center; WIDTH: 100%" id=PGFTR224 >&nbsp;</DIV>
<DIV style="TEXT-ALIGN: center; WIDTH: 100%; DISPLAY: inline; FONT-SIZE: 10pt" id=PGNUM224 >&nbsp;</DIV>
<HR style="PAGE-BREAK-AFTER: always; WIDTH: 100%; HEIGHT: 2px; COLOR: #000000" noShade>

<DIV style="TEXT-ALIGN: left; WIDTH: 100%" id=PGHDR224 >&nbsp;</DIV></DIV>
<P style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" id=PARA224.2>&nbsp;</P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA152><B><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>GEOVAX LABS, INC.</B></FONT></B> </P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0pt" id=PARA226><B><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Statements of Operations Data</B></FONT></B> </P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0pt" id=PARA227><I><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>(amounts in thousands, except per share data)</I></FONT></I> </P>
<P style="LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0pt" id=PARA228></P>
<P style="LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0pt" id=PARA229></P><BR>
<TABLE style="WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=TBL208  border=0 cellSpacing=0 cellPadding=0>

<TR id=TBL208.finRow.6>
<TD style="WIDTH: 70%">&nbsp;</TD>
<TD id=TBL208.finRow.6.lead.D8></TD>
<TD style="TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.6.amt.D8 colSpan=6>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA156><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Year Ended</FONT></P></TD>
<TD id=TBL208.finRow.6.trail.D8></TD></TR>
<TR id=TBL208.finRow.7>
<TD style="WIDTH: 70%">&nbsp;</TD>
<TD id=TBL208.finRow.7.lead.D8></TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.7.amt.D8 colSpan=6>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA157><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">December 31, </FONT></P></TD>
<TD id=TBL208.finRow.7.trail.D8></TD></TR>
<TR id=TBL208.finRow.8>
<TD style="WIDTH: 70%">&nbsp;</TD>
<TD id=TBL208.finRow.8.lead.D7></TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.8.amt.D7 colSpan=2>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA158><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">2012</FONT></P></TD>
<TD style="BORDER-BOTTOM: #000000 1px solid" id=TBL208.finRow.8.trail.D7></TD>
<TD style="BORDER-BOTTOM: #000000 1px solid" id=TBL208.finRow.8.lead.D8></TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.8.amt.D8 colSpan=2>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA159><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">2011</FONT></P></TD>
<TD id=TBL208.finRow.8.trail.D8></TD></TR>
<TR id=TBL208.finRow.9>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA160><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Grant Revenue</FONT></P></TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.9.lead.7>&nbsp;</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.9.symb.7>$</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.9.amt.7>2,657</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.9.trail.7></TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.9.lead.8>&nbsp;</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.9.symb.8>$</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.9.amt.8>4,899</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.9.trail.8></TD></TR>
<TR id=TBL208.finRow.10>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 70%">&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff" id=TBL208.finRow.10.lead.B7>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff" id=TBL208.finRow.10.symb.B7>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff" id=TBL208.finRow.10.amt.B7>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff" id=TBL208.finRow.10.trail.B7>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff" id=TBL208.finRow.10.lead.B8>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff" id=TBL208.finRow.10.symb.B8>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff" id=TBL208.finRow.10.amt.B8>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #ffffff" id=TBL208.finRow.10.trail.B8>&nbsp;</TD></TR>
<TR id=TBL208.finRow.11>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA163><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Operating expenses:</FONT></P></TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.11.lead.B7>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.11.symb.B7>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.11.amt.B7>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.11.trail.B7>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.11.lead.B8>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.11.symb.B8>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.11.amt.B8>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.11.trail.B8>&nbsp;</TD></TR>
<TR id=TBL208.finRow.12>
<TD style="BACKGROUND-COLOR: #ffffff; PADDING-LEFT: 9pt; WIDTH: 70%">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA164><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Research and development</FONT></P></TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.12.lead.7>&nbsp;</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.12.symb.7>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.12.amt.7>3,043</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.12.trail.7></TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.12.lead.8>&nbsp;</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.12.symb.8>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.12.amt.8>4,276</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.12.trail.8></TD></TR>
<TR id=TBL208.finRow.13>
<TD style="BACKGROUND-COLOR: #cceeff; PADDING-LEFT: 9pt; WIDTH: 70%">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA167><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">General and administrative</FONT></P></TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.13.lead.7>&nbsp;</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.13.symb.7>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.13.amt.7>1,753</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.13.trail.7></TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.13.lead.8>&nbsp;</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.13.symb.8>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.13.amt.8>2,972</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.13.trail.8></TD></TR>
<TR id=TBL208.finRow.14>
<TD style="BACKGROUND-COLOR: #ffffff; WIDTH: 70%">&nbsp;</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.14.lead.7>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.14.symb.7>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.14.amt.7>4,796</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.14.trail.7></TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.14.lead.8>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.14.symb.8>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.14.amt.8>7,248</TD>
<TD style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.14.trail.8></TD></TR>
<TR id=TBL208.finRow.15>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA172><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Loss from operations</FONT></P></TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.15.lead.7>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.15.symb.7>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.15.amt.7>(2,139</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.15.trail.7>)</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.15.lead.8>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.15.symb.8>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.15.amt.8>(2,349</TD>
<TD style="TEXT-ALIGN: left; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.15.trail.8>)</TD></TR>
<TR id=TBL208.finRow.16>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA175><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Interest income</FONT></P></TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.16.lead.7>&nbsp;</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.16.symb.7>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.16.amt.7>4</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.16.trail.7></TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.16.lead.8>&nbsp;</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.16.symb.8>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.16.amt.8>2</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.16.trail.8></TD></TR>
<TR id=TBL208.finRow.17>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 70%">&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.17.lead.B7>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.17.symb.B7>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.17.amt.B7>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.17.trail.B7>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.17.lead.B8>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.17.symb.B8>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.17.amt.B8>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.17.trail.B8>&nbsp;</TD></TR>
<TR id=TBL208.finRow.18>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA179><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Net loss</FONT></P></TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.18.lead.7>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.18.symb.7>$</TD>
<TD style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.18.amt.7>(2,135</TD>
<TD style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.18.trail.7>)</TD>
<TD style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.18.lead.8>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.18.symb.8>$</TD>
<TD style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.18.amt.8>(2,347</TD>
<TD style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.18.trail.8>)</TD></TR>
<TR id=TBL208.finRow.19>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 70%">&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.19.lead.B7>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.19.symb.B7>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.19.amt.B7>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.19.trail.B7>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.19.lead.B8>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.19.symb.B8>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.19.amt.B8>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.19.trail.B8>&nbsp;</TD></TR>
<TR id=TBL208.finRow.20>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA182><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Net loss per common share</FONT></P></TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.20.lead.7>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.20.symb.7>$</TD>
<TD style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.20.amt.7>(0.12</TD>
<TD style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.20.trail.7>)</TD>
<TD style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.20.lead.8>&nbsp;</TD>
<TD style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.20.symb.8>$</TD>
<TD style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.20.amt.8>(0.15</TD>
<TD style="TEXT-ALIGN: left; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.20.trail.8>)</TD></TR>
<TR id=TBL208.finRow.21>
<TD style="BACKGROUND-COLOR: #cceeff; WIDTH: 70%">&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.21.lead.B7>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.21.symb.B7>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.21.amt.B7>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.21.trail.B7>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.21.lead.B8>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.21.symb.B8>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.21.amt.B8>&nbsp;</TD>
<TD style="BACKGROUND-COLOR: #cceeff" id=TBL208.finRow.21.trail.B8>&nbsp;</TD></TR>
<TR id=TBL208.finRow.22>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA185><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Weighted averages shares outstanding</FONT></P></TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.22.lead.7>&nbsp;</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.22.symb.7>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.22.amt.7>18,316</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.22.trail.7></TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.22.lead.8>&nbsp;</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.22.symb.8>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.22.amt.8>15,736</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.22.trail.8></TD></TR></TABLE><BR>
<P style="LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0pt" id=PARA230></P>
<P style="LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0pt" id=PARA231></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0pt" id=PARA232><B><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B></B></FONT></B>&nbsp;</P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0pt">&nbsp;</P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0pt"><B><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>Balance Sheet Data</B></FONT></B> </P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0pt" id=PARA233><I><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>(amounts in thousands)</I></FONT></I> </P><BR>
<TABLE style="WIDTH: 100%; FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt" id=TBL208  border=0 cellSpacing=0 cellPadding=0>

<TR id=TBL208.finRow.27>
<TD style="WIDTH: 70%">&nbsp;</TD>
<TD id=TBL208.finRow.27.lead.D8></TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.27.amt.D8 colSpan=6>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA190><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">December 31,</FONT></P></TD>
<TD id=TBL208.finRow.27.trail.D8></TD></TR>
<TR id=TBL208.finRow.28>
<TD style="WIDTH: 70%">&nbsp;</TD>
<TD id=TBL208.finRow.28.lead.D7></TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.28.amt.D7 colSpan=2>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA191><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">2012</FONT></P></TD>
<TD style="BORDER-BOTTOM: #000000 1px solid" id=TBL208.finRow.28.trail.D7></TD>
<TD style="BORDER-BOTTOM: #000000 1px solid" id=TBL208.finRow.28.lead.D8></TD>
<TD style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.28.amt.D8 colSpan=2>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA192><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">2011</FONT></P></TD>
<TD id=TBL208.finRow.28.trail.D8></TD></TR>
<TR id=TBL208.finRow.29>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA193><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Cash and cash equivalents</FONT></P></TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.29.lead.7>&nbsp;</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.29.symb.7>$</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.29.amt.7>1,036</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.29.trail.7></TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.29.lead.8>&nbsp;</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.29.symb.8>$</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.29.amt.8>1,168</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.29.trail.8></TD></TR>
<TR id=TBL208.finRow.30>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA196><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Working capital</FONT></P></TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.30.lead.7>&nbsp;</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.30.symb.7>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.30.amt.7>1,017</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.30.trail.7></TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.30.lead.8>&nbsp;</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.30.symb.8>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.30.amt.8>476</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.30.trail.8></TD></TR>
<TR id=TBL208.finRow.31>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA199><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Total assets</FONT></P></TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.31.lead.7>&nbsp;</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.31.symb.7>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.31.amt.7>1,478</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.31.trail.7></TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.31.lead.8>&nbsp;</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.31.symb.8>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.31.amt.8>1,645</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.31.trail.8></TD></TR>
<TR id=TBL208.finRow.32>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA202><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Deficit accumulated during the development stage</FONT></P></TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.32.lead.7>&nbsp;</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.32.symb.7>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.32.amt.7>(24,767</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.32.trail.7>)</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.32.lead.8>&nbsp;</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.32.symb.8>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.32.amt.8>(22,632</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.32.trail.8>)</TD></TR>
<TR id=TBL208.finRow.33>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 70%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA205><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">Total stockholders&#146; equity</FONT></P></TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.33.lead.7>&nbsp;</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.33.symb.7>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.33.amt.7>1,151</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.33.trail.7></TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.33.lead.8>&nbsp;</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.33.symb.8>&nbsp;</TD>
<TD style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.33.amt.8>704</TD>
<TD style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom" id=TBL208.finRow.33.trail.8></TD></TR></TABLE>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA209><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>&nbsp;</I></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA210><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><B>&nbsp;</B></FONT></P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA211><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">* * * * * * * * * * * * * * *</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA212><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt" id=PARA213><FONT style="FONT-FAMILY: Times New Roman, Times, serif; FONT-SIZE: 10pt"><I>&nbsp;</I></FONT></P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt"><EM></EM>&nbsp;</P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt"><EM></EM>&nbsp;</P>
<P style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN: 0pt"><EM></EM>&nbsp;</P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt">###</P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt">&nbsp;</P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt">&nbsp;</P>
<P style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; MARGIN: 0pt">&nbsp;</P></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image1.jpg
<TEXT>
begin 644 image1.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!)`,<#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_***AO[^
M#2K*6YNIX;:V@0R2RRN$2-1R68G@`>IH2!LFHKY#_:1_X+B?L]?LY/<6G_"6
M/XUU>WW`V7AF(7PW#C!G++!UX.)"1SQ7P]\</^#H#Q=K,DUM\.OAUH>B1'Y8
M[O6[F2_F8?WA''Y2J?8EQ]:^FR_@_-L8E*G1:3ZR]U?CJ_DF?+YCQEE&#;C4
MK)R72/O/\-%\VC]G:JZQKEEX>LFN;^\M;&V3[TMQ*L2+]68@5^!6D?MA_MU?
MMZ7#KX4O_B%=Z?<Y4/X<L!I5E$.FTW,2Q@?\#DKM_"'_``;^_M,?'Z]BU#XC
M>+M(T5G^9SK&M2ZK?*3[1B1"?K**]B?!5#"_\C'&TZ;[+WG]VC_`\:'&]?%?
M\BW!5*B[OW5]^J_$_6;QS_P4*^!?PWD:/6?BW\/K:9`2T*:W!/,,?],XV9OT
MKR3Q?_P7:_9@\(N4_P"%B/JDH_@L-%OI1_WT8@G_`(]7S?\`#;_@UW\&6,<3
M>,?BCXFUB08,B:3I\-@OT#2F;(]\"O=O`G_!OO\`LS>#?+-WX7USQ')'SOU/
M6[@;OJ(#$I_*N:6%X7H_%6JU/\,4E_Y,CICBN*JWPT*5/_%)R?\`Y*SE/$?_
M``<F?L^:-N%I8?$/5V'3[-I4"*W_`'\G4_I7&:K_`,'/OPPBS]A^''CZX';[
M0]K#_P"@N]?7/A7_`();?L[^#506?P=\"RF/E3>Z<M\P_&?>:]%T#]F7X;^%
M`/[+^'W@C3=O3[+H5K#C_OE!63QO#D/@PU27^*=OR-E@>)9_'B:</\,+_F?G
M'/\`\'0_AV:4I8_!W7[H]@VN1H?R$#4Y/^#EVZO`#:_L^^()P>XU\G/Y6=?J
M)8>'-.TI0MK865L!T$4"H!^0J[6;S;)%M@/_`"K+_(T649[US#_RE#_,_+:'
M_@Y'U8GY_P!G3Q,!_LZX_P#\AU-'_P`'*D-L?].^`WBVU`ZD:L&Q^=NM?J&2
M%&20`**G^ULE_P"@#_RK/_(I91G7_0P_\I0_S/S)L_\`@YV^'4#A=3^&7CNS
M/<136TI_\>9*Z[PW_P`'*/P$UA5^VZ)\2=)9NIFTNVD5?Q2X)_2OOR_\/V&J
MJ5NK&SN0>HEA5P?S%<MK_P"S;\.O%88:IX!\%:D&Z_:M#M9L_P#?2&E_:&12
M^+"2CZ5+_G$?]G9]#X<9&7K2M^4C\W_^"P/_``5A\-_%W_@GYI5I\,+_`%F(
M?$_5I=,>>XMI+&8V5IY;W.S/)5Y)(8B02K`3KSM85[1_P2OO?@5^PI^S_I?@
M/5/'GP[T3XJ3(+GQ=#>ZK;6NH)?/\QM)#(P)\@$1;`<!D<XW,V?C[X:^!]%_
MX*,?\%MK;3/#>D:78?"/X/3,]I8Z=:I!IZ6=C.7^2-`(]MS?RLY``+).QYP:
M^[OC!_P0M_9U^,OBC5-<O/#6MZ9K.M7,MY>7ECKESOFFD8N\A$K2)DLQ)PO4
MU])F?]F8+"4\JK.=-2_>2Y4I.\OA4]5M'=+K9GS65_VIC<94S:BH5'#]W'F;
MBK1^*4+*7Q2V;Z71]7^'/%VD^,;$76D:IIVJVS<B6SN4GC/_``)216C7YG^)
MO^#:WPIHE_)??#SXN^/?"%_UBDNHXKPH>PW0F!L?C63)^P5^WE^S4%D^'WQY
MM?'5C;?<L]6OFEFD`_A$=ZDD2@^THQ7SBR3+*W^ZXV-^TXRA^/O(^E_MS,Z/
M^]8&5N\)1G^'NL_4:BORPE_X*S_M:?LDD+\;?V?CJ^E6YQ-JFEP2VRA1U9KB
M(SVQ/?`"U[I^SK_P7Z_9_P#CE)!::OJ^I?#S59>/)\06^RV+>UQ&6C"^\A3Z
M5CB.$\RIP]K3A[2'\T&IK\-?P-L-Q;EE6?LJD_9S_EFG!_CI^)]MT51\->*-
M,\::';ZGH^HV.K:;=KO@N[.X2>"9?570E6'N#5ZOG&FG9GTB::N@HHHI#/DK
M_@I;_P`%;_!'_!//2$TMH1XH^(.H0>=9Z'!*$6V0YVS73\^6A/10"[XX`&6'
MX>?M>?\`!27XO?MM:S*_C/Q3=G1V?=!H>GDVNF6_3`$*GYR.S2%W_P!JO._V
MB_BQX@^.?QU\5^+?%+3_`-OZ]J<UU>)*23;N6/[H9Y"Q@!%7^%4`X`K[9_X-
M\OV"=`_:F^..N^-O&-E!JOAWX=BW:WTV=0\-]?3%S$9%/#1QK$[%#PS&/.5W
M*?WS`9+EW#N`>.KQYJD5=RW=WTCVU=K[]6?S[C\\S'B/,%@*$N6G)V4=E9:M
MR[Z*]MNB1R'[`G_!##XH?MEV%EXDUQA\/_`UWB2+4-0@9[S4(^/FM[?*EE(Z
M.Y12#E2W2OUD_9;_`."+WP#_`&6[>VGMO",/B[78`"VJ^)`M_(7'\21$"&/G
MH53</[QZU]6JH10J@``8`'04M?E^<\9YEF$FN?DA_+'3[WN_R\D?JF2\%99E
MT4^3VD_YI:_<ME^?FREJ%_I_@_P_/=7,MIINEZ9;M--*[+%!:PQJ69B>`JJH
M))Z`"OR/^.__``5"^.__``4J^.U]\,OV6[+4=%\-6+LMQKT.+>[N8@VTW,MP
MV/LD)/**N)3ZECY8^E/^#ACX[7_P>_X)]W.E:9/);W/CW6+?097C.&%L4DGE
M&?1A`$([K(P[UZ!_P1J_9;TG]F3]@OP4;6TB36_&MA#XCUBZVCS;B2Y021(Q
M_NQQ,B`=`0QZL<[Y33P^7Y<\VKTU4J2ERTXRUBK*[DUU[+S^]89O4Q&8YDLH
MP]1TZ<8\U24=).[LHI].[?;[G\76?_!NU\9?&<":CXK^/L7]MS#=/M6\U##'
MK^^DDC9OJ5J1?^#<GXJZ'(;S2_C\@O[;]Y;'[+=V_P"\'*_O%E8ISCY@"1UP
M:_0OXK?\%&O@=\$/'-[X:\5?$SPSI&O:<0MU923,\MLQ`8*^Q2%;!!P>1D<5
MST7_``5O_9NFE5%^+OA7+$`9:4#\RF!7=#B3B:<5*$&XO:U)6MY>[L<$^&>%
MX-PG-*2WO5=[^?O;GMWPMLM8TWX9>'+;Q#+Y^OV^EVT>IR[P_F7*Q*)6W#@Y
M<,<]ZWJ\9_:__;N\`?L8_`-?B!XCU)+[3M05!HUMI\B32ZY(Z;T6`YVE2OS%
M\[0O.22H/Y]:9_P63_:\^/,$GB?X8_L^VUSX*1V,+MHFH:DTZ@\@3I)&LA'0
M^6G'I7SV`X=QV.A+$02C"]KR:BK]E<^CS#B/`X"<<-4DY3M>T4Y.W=V/UKHK
MX7_X)R?\%JM'_:\^(K?#?QYX<D^'?Q+3>D-G(S_9=2D0$O$@D`>*8`$^6^<A
M3AB?EKTK_@I-_P`%2/!G_!.CPC9C4;67Q'XSUN)I=*T&WF$32(#M\Z:3!\J+
M<"`=I+$$*#M8KA5X?S"GC%@'3?M'LNZ[I[6\[V74WI<0Y=4P3S"-5>S6[UT?
M9K>_E:[Z'TQJ&GV^K6$UK=017-M<H8I8I4#I*A&"K`\$$<8-?C]X*U&]_P""
M2G_!;./PK)?:A;_"GXG%(K.">Y=[:WM[QL0'YB0/L]TACW-EA$K$GYSG:_X?
M!?MG+HO_``FI_9YM?^$$V^?G_A&]3W>1_P`]/-\W[N.?,V;._2N-_;[_`&D?
M!_\`P6!_86;X@^%]-FT'XI?!.0:AK&AR2"68:9.R1SRPR`+YL*2"%RQ`,85\
MJ-ZEOL\BR+%X*I*CBTI4*RY).,E+ED_A;MLT]+[*Y\5GV?X/&TX5\&W&O1?M
M(*47'FBOB2ONG'6V[L?L_7S=_P`%9?VKQ^Q]^PWXP\16MS]GU_58?[#T0JVU
MQ=W(91(O^U'&)91_URQWK0_X)??M7+^V3^Q3X-\77%P+C78;?^RM<YRPOK<!
M)&;T,@V2X["85^?G_!9WQI?_`+=__!2'X;_LY^'+PKI^@3QC598SE(+FX59K
MB9AT(M[1%?VS**^=R')'/-_JV*5HT6Y3[6AO\F[+YGT>?YXH9/\`6<([RK)1
MAWO/;YI7?JCW[_@W6_9//P5_9!NO'NI6ODZ[\3KK[5&67#QZ?`62`>V]S-)Q
MU5X_2OT&K\L/BK_P6TUJ+QG:_"#]DOX9KXX@\+6R:9:Z@]I/>P/#`JQ`V]O"
M5/DJ``)78`]=H&">/\6_\%OOVEOV:(+G2OC1\*+?PO<:I;2?V1JT>C7%OY,X
M4E"4EE,5R@8`.B.C!6)W`XSZN9<-YMF6+GC)J,95'=0<DI\O3W=]%\]-CRLL
MXFRC+,)#!P<I1IJSFHMPYNOO;:OY:[GZ_P!%?"'_``3>_;D^+_\`P4?_`&/?
M%6M:?>>$/"OQ"\-:N]C:7+Z9)/IFHKY*2HDT1DWQY+%2Z,<<':<%3A_\$Y/^
M"NGB[XF?M->(?@C\?-(T?PE\0K.Z>WTM[6%K:&ZF3[]JX9W&]AAXG4[9`<#D
MIO\`!J\,XR'MUHY4?BBGJEW2MJN]MNMCWZ7$^"G[!ZJ-;X9-:-_RMWT?:^_2
MY^A9`(P>0:^>OVE_^"5_P*_:MAN)/$W@/2[35IP3_:VCH-.O@W]YGC`$A_ZZ
MJX]J\4_X*R?\%:-6_9%\:^'/AC\*M-T[Q/\`%3Q!-"TUO/`]U'I\<K!88O+1
ME+3S,1M7/"X)!WH:^JOV8-,^)=G\+K&X^*^K:%?>+KV)9KJUT>Q^SV>FL1DP
MJQ=S*5Z%\@$]!CDYQPF.R_#T\PC/V?/\-FU)I=;+IZ[FDL9@,PQ%3+I4_:<G
MQ72<4WTN^OIM\C\SOB)_P2I_:-_X)I:S<^,?V:_'VL>*M`@;S[K0&`^V2H,9
M#VIS!=\`\J%DY^5,\U]&_P#!,W_@M7X>_;'UV'P#XZT^+P/\4HLQ+;,62RUB
M1,[UAWG='*,',+DGCY6;D+]U5^6G_!P?^PUI'A[P79_M$>#(_P#A'O&'A[4[
M5-:FLCY!O0\BK!=97I<1S>6N\<L'!)^1:]_`9G0SR:P.:17M9:0JI6E?HI):
M23V_JZ^>Q^5U\BA+'Y5)^RCK.DW>/+U<6]8M;_\`#6?ZET5Q/[-7CO4_BC^S
MGX`\3:W;BUUGQ%X;T[5+^`+M\FXGM8Y9$QVP[,,>U%?#5:;A-PENG8^[I5%4
M@JD=FK_>?E5_P6:_X(E^()_'NO?%[X0Z;+K-CK$KZAKWAVU0M=VL[$M+<6R#
MF5'8EFC7+JQ.T%3A/#_^"%?_``4&TG]A[X^ZWX5\=2G2O"7COR;:YO9@572+
MV%G$4DN?NQ'S)$<_PY1CA5:OW[KYO_;#_P""4?P6_;7^T7OB?PRNE^)9P<:_
MHQ6SORV/O2$`I,?^NJ,>."*^_P`NXRIUL"\KSB+E3:LI+XE;:Z>]M-?+5,_/
MLQX+J4<<LUR:2C43NXR^%WWL^E]=//1H^B[&^@U.RAN;::*XMKA%EBEB<.DJ
M,,AE(X(((((ZU+7Y[_"+]BK]J+_@G)BR^%'C30/C'\.X6+)X3\2NVGWENO)V
M6TQ+)&??S%0DY,9->[^#_P#@I5X>TR2.Q^*WA'QK\%=7R(W;Q)IKMH\CGKY6
MI0AK9E'J[1_2OF,5DK3YL%-5H?W?B^<'[R^YKS/J<+G<6E''4W1GUYOA^4U[
MK^]/R/)/^#A[X&W_`,7/^"?LVK:;#+<7'@/6K?7)DC&6-OLDMY#CT7SU<GLJ
M,>U>D_\`!'/]IW2?VF/V"/`LEG=1/J_@_3H?#FKVVX>;;S6L8B1F'I)$J2`]
M/F(ZJ0/H:QU7PW\9O!$_V2[T;Q1X=UFW>VE:WFCO+.\A=2KH2I*LK*2".A!K
M\E_C3_P3>^/O_!*[X[ZE\2_V99M0\2^#M08M<Z)%&;RY@AR6^SW%L?FN8U).
MR2/,B@G.TY=O9RMT,?ESRBO-4ZL).4'+1.^CBWT[KS_'Q<U5?+\R6<8>#J4I
MQ4:BCJU9W4DNO9^7X?6/CW_@@[\$/B]\1_$_B[Q;_P`)1JWB#Q7K%YJ]W+%J
M/V>*(SS/((D15X5`P7)))P3GG`^+_P#@M+_P2>^$/[$7[*FD>+_`=GKUMK%U
MXDM],D-WJ)N(VA>WN9&&TJ.=T2<Y]?6NOLO^#E?QUX0C^P>*_@*JZS`-LXCU
M6>P&[O\`N9+>1E^A<UX!_P`%+/\`@L7J?_!0_P"`=AX'?X6S>%!8ZU#K'VQ=
M6:]+^7#/%Y>SR(\9\[.<_P`/3FOJ\DR[B>ECJ3Q,I>R35_?BUR^B>WR/DL\S
M'A>M@:RPL8^V:=O<DGS>KCOYW-[XPZ'#\?\`]HW]A?X8^*9Y/^$+F^'_`(8=
MK=G*I.;J1EG4'L91!%%D<C:*_4W_`(*`?MW>%_\`@F;\"=&UNZ\-7.JPW=Y'
MHVE:1INRUBC"Q,V-V"L<:(F`%4\E0!C)'Q5\9?\`@GQJ7[<7_!,S]GWQ]\*[
M^&3XG?#+PK8VD4<%P(I+T0QIOMED)'EW$$Z,4R0,LX)R5(X5O^"W7C/P.^@Z
M1\??V=O^$F\:>"GD^RW=X\FEL)F0Q/.UM);R)YI3(WK@?.VU5!KGQ6!_M1T?
M8KVBHN:G2YE&5^9N^K6DM+O]3HPN/_LI5G6E[-UU"4*O*Y1MRI6T3UCK9;?*
MQ\^?MK_\%#])_;9_:X^&GQ#\`_#[4?!7CK1+V".>:.\%W+J\L<\;6A"I$A,B
M$,N?F+`HO10*^I?A[X/T[]J?_@XX\91>/(H]1M/!4<MQI&GW8#P,UI##';J$
M/!`+M<8[LI)R":DT+_@XW\.:=K%M,O[-RV)20$W%OJ\7FQ#NR_Z&O./<?45T
M/_!0+]E/QG\1OB5X,_;)_9?EFU36KRQMM0U#3K1%>\EQ"$$@B&?,)A_<30#Y
MAL/#9?;Z%6I4I<N$K4/JRE3G3A)S4]9.+2<EJEI97[Z'G4J=.KS8RC7^M.-2
MG4J1C!P]V*:;47I)ZW=NVI^J-?CO\6_A5X?^!O\`P<*Z-X>\,6-LGA[XE6?D
M>(M%A7;:RQ:A:317<+(/X6`\\KT#,",`"M9O^#CCXG-HG_"/#X!,/B$1Y&/M
M5SY/FXQG['Y/F]?X/-S_`+5>B_\`!)G_`()\_$OQ%^TIJ_[3?Q]CN+;QKJXE
M;1],NXPEU`TL?E-<21_\L52',4<1P0I.0NU,_.9=E>(R2CB,1F#45*$H1CS)
MN<GLTDWHM[[H^ES+-<-GM;#8;+DYN%2,Y2Y6E"*W3;2U>UMF>)?\$]/VAX_^
M"0'[6/Q\^$/CR\=?#>G6EUK>DF9PAO)[:(S6XCS@;[JU9>/[Z1K7D_[,W@WQ
M3XI_8^_:H_:EU<RR>(=;MY=!TZYVG)?4+N$:E-'GE=L,XC5EZ"20<8KZ6_X.
M._V'-1^(VK^`/B;X4TN>_P!6O+F/PEJ<%LFZ2=I&+6;X'^T98RQZEH1Z5]T?
M!7]A?PQ\//V"M.^!>HP)<Z-+X??2M6DA^5KF>=6:YG0XX8S.[J>J_+Z5Z>)S
M_"4L'3S**O5Q#@JB\J;7/_X%IIU3/+PW#^,JXRKEDG:EAU-TWYU$^3_P'77H
MT>&_\&^'P;\->`_^">FA>)M+AMI->\:WEY=:Q>!09F:&YE@BA+=0J)&&"]-T
MCG^*O?\`_@H7\'?#?QR_8M^(^B^*(+:33X=!O-0BGE4$V%Q!`\L5PI/W2C*#
MGN-P/!(/YA_#KQK^T7_P03\::[X9N_!TWQ)^$.I7CW=G<Q+*MH2<*)HYT5_L
MLK*%#Q2*PRN5R/G9O[0__!23]H?_`(*S>";WX;?"?X1ZKX>\.ZI&1K,UM*]W
M)<PKAC%)=,D44,;8Y3&Y^%!(8HW'BN'L9B<U>9T:L71E+G53F245>]M[IQ6E
MK=.AVX3B+!X7*5E=:C)5HQY'3Y7>3M:][6:D];WZ]3W#_@V!4)^RY\10.@\4
MJ/\`R5BJA_P<>?L\>#-'^'WAOXRVNM0^%OB9I=_#868@REQKZ*=P(*?,LMOC
M>)>`%^0G)B`YS_@W\^/_`(._99_9/^+3_$#7K+PM-H>NK?75K?$QW7EFW5!L
MAQOD8O&RA4!;<,8Y%<C\'/AYXH_X+P_\%!;KQ[XQT[4-*^"7P_E6.TT^<,B3
MPAMT=H#T,TQ'F3LI.U?EW#]U7=4H5*/$.(S2I)PHTM9/^:\5:"[\W]6=C@IU
MZ=;AS#953BIUJND5_+:3O-VVY?ZNKEC_`(-Z/`OAG]I/]HWQ[\6O'OB0^*/B
MYIDOGVEE?C=-"DPQ)J()X<Y;R0%XB!Y`WQX_8VOR8_X*6_L$>-OV'/VH-!_:
M+_9QT6Z$<E\HUC0-(LFE2VG?AL01#+6MP"5=`!L=N"-Z[/O7X&_M%_$[XZ>&
M+*\E^#6J_#U[B%6FD\5:G#'Y3D#<(X(=\[@'./-6$G':OG>*H+'2AFF'J)TY
MI+E;BG!QWC;33JK+KZ-_1\)U'@(SRK$TVJD&WS)2:J*6TKV>O1W?3U2]NO+R
M'3K26XN)8X((5+R22,%2-0,DDG@`>M?-GQ[^%MU_P40U#2_"US:SZ?\`!72M
M0AU/6;NX0QS^-)86WPV=LA^9+(/AY)V`,A5%B^7,E?0L.@F^TM(-8:VU20/Y
MC9MPD6[MA"6X';))]ZN2:A!%=+`T\*SLNY8RX#D9QD#KC)`_&OD\+B7AY^TI
M?&MGV\UY]GTWWLU]=BL,L3#V57X'NN_D_+NNNVUTY(($MH4CC18XXU"HBC"J
M!P`!V%%+'(LJ*RL&5AD$'((]:*Y#L%HHHH`*22-98V1U#*PP01D$>E+10!P=
MQ^S#X`?6CJ=KX6TS2-39MS7ND*=,N7/JTEN49OQ)KH=$\(2^'\+#K.KW$(/$
M=Y*MQ@>F]EW_`)L:VZ*VEB*DE:4F_77\S&&'IQ=X12]-/R$9%;J`?J*3R4_N
MK^5.HK$V&I$L6=JJNXY.!C)I60/U`/U%?*?[<'[<&K_LX?M8?!SPGIMOKE_H
M>MP:IJOBBVT70GUC4'M88T2V"11JSJK3L0SC&`.O8^.^"O\`@H[\1OCGX[T9
M?#&H?V5IGC;XRKX4T>RU#1HXKRWT&PM!-J3LCC<)6,D8^?YD*L.*]W#\.XNM
M1CB%91:YKN_1M=M_=<O17\CP,1Q'@Z-:6'=W)2Y;*V[2??:\E'_$[>9^AODI
M_=7\J(XEB!"JJ@G)P,9-?!'[._[='Q2^/GACX1>!;/6-+'Q)U?6]7O?&^JI8
M0F/2-"TW4)H&8P_=CDG(BAC;!`96)'.:WM;_`."@'BC2/V7+SQG#JFD'Q#\8
M_%]SHWPJL[]([6VL-.\P6\%[<,0"8@D4EX[OD8FB3@$553AW%PJ>R;5[VW?=
MJ^VWNR=W]E-OI=4^),).G[5)VM?9=D[;[^]%67VFDNMOMO`SG`SZT5\%?#?_
M`(*#>._B1\$/V8O(UG28?%_Q%\7WMEXHN1:1-%-INE27)U`QKC:FZ*.-@ZCY
M0V1C-<GX#_;.^/\`IWP(^'WQYU?QGX>U+P?X_P#&$6CQ>!KCPW%;74=C<7TM
MO$8;N-][S;(]ZJR8P<G=@@Z+AC%7:E**=^57;U=Y*RTZN$K-V6FMC/\`UHPM
MDXQDUR\S:2T5HN[UZ*<;I7>NB9^D)&>M%?G]??M9_&BT_;(N/#_B#QM:?#H7
M7C7^R?#/AG7O"!'A_P`6Z1Y@$;P:Q&KO]LECRRJ650^%V@G:/I']H[]N[PS^
MR]X_O-%\2V%_';6G@Z\\7+?H\8BN!;3QPFS168$SN\L04="749KDK9'B83A3
MA:;FKJU]OFDG_P!NW6^NAUT,]PM2$ZD[P4'9N5M_DVU_V]9[::GN%``48`P*
M^4/'7_!4ZR^&GQ+\,>&]=\`:QI=QKD^D65W'<:YIJWUC=:B(]D4=GYWGW`B,
MBK*Z*`K!@-P&3I:#_P`%,].UP7GB4?#WQHOPAMVU)(_'T:P3Z?)]@64S2M`C
MF>.!FA>..5E^=\#`SQ+R/&J*GR:/;5:^2UU;Z):OHBEGN!<G#GU6^CT\WIHE
MU;T75GTS):12R*[11LZ_=8J"14@`48``%?'OQ&_X*4Z[I_[.GB7Q/?\`PN^)
M'P^6ZT6UU#POJDMM9:B-0%[<Q6UL`HE,<=UNG23[-,0=@8GIBKNF_P#!4.VT
MSXB:;X;N?`WBW4=&7QY_PK&X\7M)9PVMQJZ`J\BVXD\TQY25G95"(JGDGY:K
M^P<:XN2BG:_5=$F];V>^R=[]"/[?P2DHN35[='U;2TM=;;M6MU/K6BOC#X=?
M\%MOAW\1O'$EA::#KLVCWEGJUWHU[97-I?7FJC3H)9Y@UA%*;FV\R.&0P^<B
M^9@<#->L_L0?MOP?MK>']0U6R\*W>AZ=;1P3VUW_`&M9:E;W2RJ6\IFMY&,-
MQ&`/,AD567<.348G),;AX.I6I\J5KW:ZMKOO=.ZW5G<TPV>8'$35.A4YF[VL
MGT2?;:S33V=U:Y[M7E_Q<_96T?XP^-X==O=4U?3[JWAA2,V+1QNCPR^=#('*
M$Y1_F'N!VR#ZA17GT:\Z4N:F[,]&M0A5CR5%=&-\.?`UE\+_`(>Z#X:TWS?[
M.\.Z=;Z9:^80S^5#$L:;B`,G:HSQ16S142DY-RENRXQ44HQV04445)04444`
M%%%%`!1110!Y^G[-OA\?M0/\6WEU.7Q2?#8\*QH\ZFSM[/[3]I)2/;D2-)C+
M%CP,8KA/A)_P3G\`_!SQ-X!U>PN?$=_?_#F76+G3);^[CE,UQJC$W<\VV-=\
MA7"*1@!5'!/->]T5V1S#$QBX*;M:WRLU;[I-?-G%++L-*2FX*Z=_G=._WQ3^
M2/G_`.&W_!-KX>_"'3/BU'X<N/$>F:A\9&NCK&J1W<1O;)+@S%H[1C$5B56G
MD9<JQR026VKB[J/_``3H^%7B/QIX>U77]`B\46/A'PW%X6T/0M:BAO='TFUC
MV_/%;O&1YS!$5I&+':H`P!7N=%:2S7&.3FZCN^M]=DM_16]-"(Y3@U%05)67
M2VF]]O5W]=3YI\.?\$J/ACX2>`:;<>)[*VTZ'7X-+MH;N&.'1EUF,1W?V91$
M/+VH`L?4*.H:D^"G_!*SX>?!O7O#%[<ZY\0O&\/@AED\-Z?XHUYKW3M!D4$+
M);VR(D2NH/!96QP1@@$?2]%:2SK'23BZKUWU]?SN[][ON91R3`1DI*E'3;3M
M:WW65NUEV/F;X?\`_!*OP!\/?$OAR2+Q#\0M3\*^#-7_`+>\/>#M0UE9M!T2
M]#,\<L,0B$I,;N[())7`+MP<UWOQ^_8E\#?M+?%OP!XR\50:A=:E\.+B2YTV
MWCG"6ERSO#(!<(5)D5)((G49`RO.0<5ZY16<\UQ<JBK.H^9)J_76]_ON[O=]
M36&4X.--T537*VG;II:WW65ELCYMC_X)=^`8_B_-XM_MKQFXF\;#X@G1WO+=
MM.&L#_EL<P><RYP0C2LJ8^0(,@L\(_\`!*_X=>%=#U#0I-7\=ZMX.GL=1T[3
M_#-[K1_LK0H;_?\`:?LR1HCECYC;6F>4IG*E3S7TK15O.<=:WM7T_#;YZO7?
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MZS+`US>_9HVC@4K;Q0PKM5FY6,,Q8EF8\UZS14ULTQ=6,HU)MJ6_GK?\TF^[
BU>I5'*L)1E&5.FDX[>6EOR;2[+1:!1117`>@%%%%`'__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
